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The data presented in this paper describe trends in treated problem drug use in seven
health board areas, namely: the Midland, Mid-Western, North Eastern, North Western,
Southern, South Eastern and Western Health Boards. The total numbers include 7,545
cases who lived and were treated in the seven health boards between 1998 and 2002.
In this paper, problem drug use is described in relation to person, place and time. This
paper will assist policy makers, service planners and public health practitioners to
develop appropriate responses to problem drug use in the future. 
The analysis presented in this paper is based on data reported to the National Drug
Treatment Reporting System. 
The main findings and their implications are: 
• Both the incidence and prevalence of treated problem drug use almost trebled
between 1998 and 2002. For example, the incidence of treated problem drug use
increased from 24.8 per 100,000 of the population in 1998 to 69.7 per 100,000 in
2002. This observed increase may be explained by a true increase in use, an increase
in access to treatment services, new legislation encouraging more people into
treatment, or an increase in the number of centres reporting cases to the NDTRS.
The most likely explanation is a combination of all these factors. 
• The incidence of treated problem drug use for the reporting period was highest in
the Southern Health Board area, followed closely by the South Eastern Health Board
area. The Western Health Board area had the lowest incidence, indicating lower
drug use rates than in the rest of Ireland, lower access to or uptake of appropriate
treatment services, or lower levels of participation in the NDTRS. This requires
investigation. 
• The total number of cases reporting cannabis as their main problem drug trebled,
increasing from 392 in 1998 to 1,328 in 2002. The numbers reporting problem
opiate use also increased steadily, from 116 in 1998 to 439 in 2002. Opiate use was
more common in the health board areas bordering the Eastern Regional Health
Authority area. The second most frequently reported main problem drug was
ecstasy for new cases and opiates for previously treated cases. Though small, the
number of new cases reporting cocaine use increased from six in 1998 to 42 in
2002, indicating the early stages of an epidemic in these health board areas. These
findings indicate that treatment services must cater for a wide spectrum of illicit
drugs rather than focus on one or two drugs and be capable of adjusting treatment
approaches in accordance with changing patterns of problem drug use.
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• Although there was a small percentage decrease in polydrug use, from 84 per cent of cases in 1998 to 79
per cent in 2002, it remained a common practice and is associated with poorer treatment outcomes. 
• The number of cases who reported injecting trebled, increasing from 96 in 1998 to 284 in 2002. Injectors
have a higher risk of acquiring blood-borne viral infections and experiencing overdose than non-injectors. 
• The proportion of cases under 18 years old increased by just over three per cent during the reporting period
and, as expected, was much higher for new cases than for those previously treated. Those under 18 years
old require different approaches to treatment and it is important that this is a consideration during service
planning. 
• The main problem drug reported by new cases was examined by selected socio-demographic and drug-
using characteristics and some important relationships were identified. Young teenagers initiated drug use
with cannabis and volatile inhalants. The use of opiates, ecstasy and amphetamines was commenced in mid
to late teens. There were differences in type of drug used by males and females, with very high proportions
of males treated for cocaine and cannabis use compared to their female counterparts. The highest rates of
employment were among those using drugs commonly associated with social events, and the lowest rates of
employment were among those who used opiates and benzodiazepines. This observation (along with the
high rates of early school leaving) has important implications for the social and occupational reintegration of
opiate and benzodiazepine users. 
• Incidence is a term used to describe the number of new cases of disease or events that develop among a
population during a specified time interval.  For example, in 2001, ten opiate users living in a specific county
sought treatment for the first time.  The incidence is the number of opiate cases divided by the population
living in the county (say 31,182 persons in this example) expressed per given number of the population, i.e.,
per 100, per 1,000, per 10,000, etc.
– The calculation in this case is as follows: (10/31,182) x 10,000, which gives an incidence rate of 3.2 per
10,000 of the specific county population in 2001.
• Prevalence is a term used to describe the proportion of people in a population who have a disease or
condition at a specific point or period in time.  For example, in 2001, ten opiate users living in a specific
county sought treatment for the first time, 20 opiate users returned to treatment in the year and five opiate
users continued in treatment from the previous year; in total there are 35 people treated for problem opiate
use in 2001.  The prevalence is the total number of cases (35) divided by the population living in the county
(31,182 persons) expressed per given number of the population, i.e., per 100, per 1,000, per 10,000, etc. 
– The calculation in this case is as follows: (35/31,182) x 10,000, which gives a prevalence rate of 11.2 per
10,000 of the specific county population in 2001.
• The median is the value at the mid-point in a sequence of numerical values ranged in ascending or
descending order. It is defined as the value above or below which half of the values lie. Unlike the mean
(average), the median is not influenced by extreme values (or outliers).  For example, in the case of five drug
users aged 22, 23, 24, 24 and 46 years respectively, the median (middle value) is 24 years, whereas the
mean is 27.8 years.  While both the median and the mean describe the central value of the data, the median
is more useful since the mean is influenced by the one older person in this example. 
Glossary of Terms
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The National Drug Treatment Reporting System (NDTRS) is an epidemiological database on treated problem drug
use in Ireland. It was established in 1990 in the Greater Dublin Area and was extended in 1995 to cover other
areas of the country. The reporting system was originally developed in line with the Pompidou Group’s Definitive
Protocol (Hartnoll 1994) and subsequently refined in accordance with the Treatment Demand Indicator Protocol
(EMCDDA and Pompidou Group 2000). The NDTRS is co-ordinated by staff at the Drug Misuse Research Division
(DMRD) of the Health Research Board (HRB) on behalf of the Department of Health and Children. 
Drug treatment data are viewed as an indirect indicator of drug misuse as well as a direct indicator of demand
for treatment services. These data are used at national and European levels to provide information on the
characteristics of clients entering treatment, and on patterns of drug misuse, such as types of drugs used and
consumption behaviours. They are ‘valuable from a public health perspective to assess needs, … and to plan and
evaluate services’ (EMCDDA 1998: 23). Information from the NDTRS is made available to service providers and
policy makers and is used to inform local and national drug policy and planning. For example, in 1996 NDTRS
data were used to identify a number of local areas with problematic heroin use (Ministerial Task Force 1996).
These areas were later designated as Local Drugs Task Force Areas and are continuing to provide strategic
responses to drug misuse in their communities. 
The monitoring role of the NDTRS is recognised by the Government in its document Building on Experience: National
Drugs Strategy 2001–2008. Data collection for the NDTRS is one of the actions identified and agreed by Government
for implementation by health boards:  ‘All treatment providers should co-operate in returning information on
problem drug use to the DMRD of the HRB’ (Department of Tourism, Sport and Recreation 2001: 118). 
Methods
Compliance with the NDTRS requires that one form be completed for each person who receives treatment for
problematic drug use at each treatment centre in a calendar year. Service providers at drug treatment centres
throughout Ireland collect data on each individual treated for drug misuse. At national level, staff at the DMRD
of the HRB compile anonymous, aggregated data. 
For the purpose of the NDTRS, treatment is broadly defined as ‘any activity which aims to ameliorate the
psychological, medical or social state of individuals who seek help for their drug problems’. Clients who attend
needle-exchange services are not included in this reporting system.  Up to 2004, clients who reported alcohol as
their main problem drug were not included in this reporting system. Treatment options include one or more of
the following: medication (detoxification, methadone reduction and substitution programmes), addiction
counselling, group therapy, psychotherapy and/or life skills training. Treatment is provided in both residential and
non-residential settings. In the seven health board areas, data returns to the NDTRS for clients attending treatment
services during 2002 were provided by 79 treatment services: 63 non-residential and 16 residential (Table 1). 
The main elements of the reporting system are defined as follows: 
• All cases treated – describes individuals who receive treatment for problematic drug use at each treatment
centre in a calendar year, and includes both 
(a) Previously treated cases – describes individuals who were treated previously for problematic drug use
at any treatment centre and have returned to treatment in the reporting year, and also those
individuals continuing in treatment from the preceding calendar year; and
(b) New cases treated – describes individuals who have never been treated for problem drug use. 
In the case of the data for ‘previously treated cases’ there is a possibility of duplication in the database; for example,
where a person receives treatment at more than one centre. For those receiving methadone maintenance or
detoxification, this possibility is considered to be small since the introduction of the Misuse of Drugs Regulations in
1998, whereby precautions are taken to ensure that methadone treatment is available from one source only. 
Introduction
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The total number of drug treatment services available in the seven health boards outside the Eastern Regional
Health Authority area and participating in the NDTRS increased between 1998 and 2002 (Table 1). The largest
increase was in outpatient treatment services, while there was a small increase in the number of residential
treatment services. The number of general practitioners participating in the NDTRS was very low. In 2002, there
were 49 general practitioners prescribing methadone treatment outside the Eastern Regional Health Authority
area but only four of these provided returns to the NDTRS. There are no low-threshold services providing low-
dose methadone therapy outside Counties Dublin, Kildare and Wicklow. The prison service does not participate
in the NDTRS, although it does provide drug treatment services. 
Table 1   Number and type of services providing treatment for problem drug use and number 
of cases* treated (in brackets) in the seven health board† areas and reported to the NDTRS, 
1998 to 2002
Drug services 1998 1999 2000 2001 2002         
Outpatient 36 (592) 35 (754) 50 (1262) 60 (1330) 59 (1510)  
Residential 12 (197) 10 (208) 13 (290) 13 (625) 16 (745)  
Low threshold 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)  
General practitioner 0 (0) 5 (8) 3 (4) 5 (14) 4 (6)  
Prison 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)  
* Numbers include cases living in the Eastern Regional Health Authority but treated in another health board area, and exclude cases living in
one of the seven health board areas but treated in the Eastern Regional Health Authority and recorded in the NDTRS.
†  Midland Health Board, Mid-Western Health Board, North Eastern Health Board, North Western Health Board, Southern Health Board, South
Eastern Health Board and Western Health Board. 
The analysis presented provides an overview of the following: service provision for problem drug use; numbers
treated for problem drug use; incidence and prevalence of treatment for problem drug use; main problem drugs;
risk behaviours; socio-demographic characteristics of cases; and relationship between the main problem drug and
selected characteristics. The study population consisted of cases living and treated in the seven health board areas. 
Service provision
Numbers treated
Of the 8,117 cases treated for problem drug use in the seven health board areas between 1998 and 2002, 7,545
(93%) lived and were treated in these areas, 537 (7%) lived in the Eastern Regional Health Authority area, 30
(0.4%) were not resident in Ireland and five (0.1%) had no address recorded. This paper describes the 7,545
cases who lived and were treated in the seven health board areas in relation to person, place and time.  
Overall, the number of new and previously treated cases living in the seven health boards (outside the Eastern
Regional Health Authority area) and reported to the NDTRS trebled between 1998 and 2002 (Table 2). Each
year, over half of cases were treated for the first time during the period under review.  
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Analysis of treatment data
As a result of small numbers in 1998 and a high rate (12%) of treatment status unknown, some of the
comparisons are limited to the time period 1999 to 2000.  
The data presented in this paper provide a description of problem drug use in seven health board areas, namely:
the Midland, Mid-Western, North Eastern, North Western, Southern, South Eastern and Western Health Boards.
The total numbers include cases who lived and were treated in the seven health boards between 1998 and 2002
and excludes cases resident the Eastern Regional Health Authority and cases not resident in Ireland who were
treated in any of the seven health boards. Cases living in any of the seven health board areas and treated in the
Eastern Regional Health Authority area were not included as the returns to the reporting system for 2001 and
2002 are not yet complete. 
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Table 2   Number (%) of cases* living and treated in the seven health board† areas by treatment
status reported to the NDTRS, 1998 to 2002
Treatment status 1998 1999 2000 2001 2002  
Number (%)         
All cases 789 970 1556 1969 2261  
Previously treated cases 269 (34.1) 388 (40.0) 565 (36.3) 746 (37.9) 886 (39.2)  
New cases 423 (53.6) 556 (57.3) 952 (61.2) 1144 (58.1) 1273 (56.3) 
Status unknown 97 (12.3) 26 (2.7) 39 (2.5) 79 (4.0) 102 (4.5)  
* Numbers exclude cases living in the Eastern Regional Health Authority but treated in one of the seven health boards and cases living in
one of the seven health board areas but treated in the Eastern Regional Health Authority. 
† Midland Health Board, Mid-Western Health Board, North Eastern Health Board, North Western Health Board, Southern Health Board, South
Eastern Health Board and Western Health Board.
The data pertaining to cases who lived and were treated in the seven health board areas between 1998 and
2002 were examined by health board area where the cases resided (Table 3). Although there was considerable
variation between the seven health boards in the number of cases treated, the overall figure included cases
from every county in Ireland. The total number of cases living in each of the health board areas and treated for
problem drug use increased between 1998 and 2000. In 2001 the number treated in the Midland Health Board
area fell sharply and increased again in 2002, indicating a possible lapse in participation rather than a true
decrease in treatment seeking. In 2002, the numbers treated in the North Eastern Health Board area decreased.
According to staff at the North Eastern Health Board, the reduction in numbers reported to the NDTRS in 2002
was due to a reduction in returns to the reporting system rather than an actual reduction in the demand for
services. Staff at the North Eastern Health Board’s Public Health Department have addressed the reduction in
returns to the NDTRS for 2003. The highest number of cases treated in the seven health board areas lived in
the Southern Health Board area, followed closely by numbers living in the South Eastern Health Board area. 
Previously treated cases are an indirect indicator of chronic drug use among the population living in a
geographical area. From 1998 to 2002, the number of previously treated cases who returned to, or continued
in, treatment and lived in one of the seven health board areas increased each year in five of the health board
areas (Table 3). The number of previously treated cases living in the Mid-Western and North Eastern Health
Board areas decreased by 9 and 10 per cent respectively in 2002 compared to 2001. The reason for the drop in
previously treated cases in the Mid-Western Health Board is not clear, while the reason for the decrease in the
North Eastern Health Board is mentioned above.
New cases are an indirect indicator of recent trends in problem drug use. From 1998 to 2002, the number of
new cases who lived and were treated in one of the seven health boards increased each year in five of the
health board areas (Table 3). The number of new cases living in the North Eastern Health Board area decreased
by 20 per cent in 2002 compared to 2001. The number of new cases living in the Midland Health Board area
decreased by 29 per cent between 2000 and 2002; the reason for this is not clear. Anecdotal reports suggest
that this is not a true decrease in problem drug use and that the reduction may be explained by a delay in
entering treatment, possibly because of a shortage of methadone treatment places in this health board.  
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Table 3   Number (%) of cases* treated in the seven health board† areas by health board of
residence and treatment status reported to the NDTRS, 1998 to 2002
Health board of residence 1998 1999 2000 2001 2002  
Number (%)       
All cases 789 970 1556 1969 2261  
Midland Health Board 87 (11.0) 129 (13.3) 160 (10.3) 128 (6.5) 173 (7.7)  
Mid-Western Health Board 91 (11.5) 156 (16.1) 203 (13.0) 247 (12.5) 244 (10.8)  
North Eastern Health Board 73 (9.3) 131 (13.5) 254 (16.3) 367 (18.6) 310 (13.7)  
North Western Health Board 46 (5.8) 38 (3.9) 78 (5.0) 100 (5.1) 132 (5.8)  
Southern Health Board 298 (37.8) 296 (30.5) 499 (32.1) 621 (31.5) 705 (31.2)  
South Eastern Health Board 186 (23.6) 191 (19.7) 336 (21.6) 428 (21.7) 550 (24.3)  
Western Health Board 8 (1.0) 29 (3.0) 26 (1.7) 78 (4.0) 147 (6.5)    
Previously treated cases 269 388 565 746 886   
Midland Health Board 45 (16.7) 46 (11.9) 59 (10.4) 60 (8.0) 86 (9.7)  
Mid-Western Health Board 30 (11.2) 64 (16.5) 79 (14.0) 90 (12.1) 82 (9.3)  
North Eastern Health Board 2 (0.7) 41 (10.6) 76 (13.5) 137 (18.4) 123 (13.9)  
North Western Health Board 14 (5.2) 14 (3.6) 15 (2.7) 28 (3.8) 58 (6.5)  
Southern Health Board 103 (38.3) 132 (34.0) 203 (35.9) 205 (27.5) 262 (29.6)  
South Eastern Health Board 69 (25.7) 77 (19.8) 130 (23.0) 196 (26.3) 224 (25.3)  
Western Health Board 6 (2.2) 14 (3.6) 3 (0.5) 30 (4.0) 51 (5.8)    
New cases 423 556 952 1144 1273  
Midland Health Board 41 (9.7) 78 (14.0) 93 (9.8) 67 (5.9) 66 (5.2)  
Mid-Western Health Board 56 (13.2) 88 (15.8) 112 (11.8) 130 (11.4) 145 (11.4)  
North Eastern Health Board 1 (0.2) 82 (14.7) 172 (18.1) 208 (18.2) 167 (13.1)  
North Western Health Board 29 (6.9) 24 (4.3) 61 (6.4) 70 (6.1) 71 (5.6)  
Southern Health Board 182 (43.0) 162 (29.1) 295 (31.0) 403 (35.2) 424 (33.3)  
South Eastern Health Board 112 (26.5) 107 (19.2) 196 (20.6) 220 (19.2) 310 (24.4)  
Western Health Board 2 (0.5) 15 (2.7) 23 (2.4) 46 (4.0) 90 (7.1)    
* Numbers exclude cases living in the Eastern Regional Health Authority but treated in one of the seven health boards and cases living in one
of the seven health board areas but treated in the Eastern Regional Health Authority.
†  Midland Health Board, Mid-Western Health Board, North Eastern Health Board, North Western Health Board, Southern Health Board, South
Eastern Health Board and Western Health Board.
In order to adjust for variation in population size in each health board area, the actual incidence of drug use in
each area was calculated using the average number of new cases over the five-year period living in each of the
seven health board areas; this average was divided by the population aged 15 to 64 years living in the respective
health board areas, using the census figures for 2002 (Census 2003). The incidence rate for the reporting period
was highest in the Southern Health Board area, followed closely by the South Eastern Health Board area (Figure
1). The Western Health Board area had the lowest incidence, indicating one or more of the following: lower drug
use rates than in the rest of Ireland, lower access to or uptake of appropriate treatment services or lower
participation in the NDTRS.
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Figure 1   Average annual incidence of treated problem drug use in each health board area
among persons aged 15 to 64 years living and treated in the seven health board areas, based on
returns to the NDTRS per 100,000 of the population, 1998 to 2003 (Central Statistics Office 2003)
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Incidence and prevalence of treatment
Figure 2 presents the incidence and prevalence of treated problem drug use from 1998 to 2002 among persons
aged between 15 and 64 years in the seven health board areas, expressed per 100,000 population. Both the
incidence and prevalence of treated problem drug use almost trebled during the reporting period. For example,
the incidence of treated problem drug use increased from 24.8 per 100,000 of the population in 1998 to 69.7
per 100,000 in 2002. This observed increase may be explained by a true increase in use, an increase in access to
treatment services, new legislation encouraging more people into treatment, or an increase in the numbers of
centres reporting cases to the NDTRS. The most likely explanation is a combination of all these factors. 
Figure 2   Incidence and prevalence of treated problem drug use among persons aged between 15
and 64 years living and treated in the seven health board areas, based on returns to the NDTRS
per 100,000 population, 1998 to 2002 (Central Statistics Office 2003) 
Main problem drugs
The number of cases reporting cannabis as their main problem drug increased substantially, from 392 in 1998 to
1,328 in 2002, and this was the most frequently reported main problem drug (Table 4). The same trend in
cannabis use was noted for both new and previously treated cases. The numbers reporting problem opiate use
also increased substantially during the period under review. The second most frequently reported main problem
drug was ecstasy for new cases and opiates for previously treated cases between 1998 and 2002. The numbers
of new cases reporting cocaine use, though small, increased consistently during the reporting period, indicating
the early years of an epidemic. The number of previously treated cases reporting benzodiazepine use also
increased during the same period. 
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Table 4   Main problem drug reported by cases* living and treated in the seven health board†
areas by treatment status and reported to the NDTRS, 1998 to 2002
Main problem drug     1998    1999    2000    2001 2002   
Number (%)         
All cases 789 970 1556 1969 2261  
Cannabis 392 (49.7) 543 (56.0) 924 (59.4) 1135 (57.6) 1328 (58.7)  
Ecstasy 138 (17.5) 155 (16.0) 250 (16.1) 266 (13.5) 242 (10.7)  
Opiates 116 (14.7) 151 (15.6) 220 (14.1) 362 (18.4) 439 (19.4)  
Amphetamines 44 (5.6) 41 (4.2) 28 (1.8) 17 (0.9) 28 (1.2)  
Benzodiazepines 35 (4.4) 22 (2.3) 42 (2.7) 50 (2.5) 63 (2.8)  
Cocaine 22 (2.8) 18 (1.9) 30 (1.9) 49 (2.5) 77 (3.4)  
Volatile inhalants 17 (2.2) 24 (2.5) 29 (1.9) 37 (1.9) 43 (1.9)  
Other substances 25 (3.2) 16 (1.6) 33 (2.1) 53 (2.7) 41 (1.8)  
Previously treated cases 269  388 565 746 886   
Cannabis 109 (40.5) 177 (45.6) 304 (53.8) 362 (48.5) 432 (48.8)  
Opiates 54 (20.1) 106 (27.3) 127 (22.5) 223 (29.9) 260 (29.3) 
Ecstasy 44 (16.4) 49 (12.6) 65 (11.5) 85 (11.4) 82 (9.3)  
Benzodiazepines 19 (7.1) 14 (3.6) 22 (3.9) 23 (3.1) 45 (5.1)  
Amphetamines 16 (5.9) 17 (4.4) 11 (1.9) 14 (1.9) 15 (1.7)  
Cocaine 13 (4.8) 7 (1.8) 17 (3.0) 18 (2.4) 27 (3.0)  
Volatile inhalants 5 (1.9) 8 (2.1) 7 (1.2) 2 (0.3) 8 (0.9)  
Other substances 9 (3.3) 10 (2.6) 12 (2.1) 19 (2.5) 17 (1.9)  
New cases 423 556 952 1144 1273  
Cannabis 245 (57.9) 357 (64.2) 600 (63.0) 724 (63.3) 843 (66.2)  
Ecstasy 84 (19.9) 101 (18.2) 179 (18.8) 176 (15.4) 156 (12.3)  
Opiates 35 (8.3) 39 (7.0) 83 (8.7) 126 (11.0) 148 (11.6)  
Amphetamines 20 (4.7) 21 (3.8) 17 (1.8) 3 (0.3) 13 (1.0)  
Benzodiazepines 12 (2.8) 8 (1.4) 19 (2.0) 25 (2.2) 18 (1.4)  
Volatile inhalants 9 (2.1) 15 (2.7) 21 (2.2) 34 (3.0) 34 (2.7)  
Cocaine 6 (1.4) 10 (1.8) 12 (1.3) 26 (2.3) 42 (3.3)  
Other substances 12 (2.8) 5 (0.9) 21 (2.2) 30 (2.6) 19 (1.5)  
* Numbers exclude cases living in the Eastern Regional Health Authority but treated in one of the seven health boards and cases living in
one of the seven health board areas but treated in the Eastern Regional Health Authority. 
† Midland Health Board, Mid-Western Health Board, North Eastern Health Board, North Western Health Board, Southern Health Board, South
Eastern Health Board and Western Health Board.
Of the new cases living in each of the seven health board areas between 1998 and 2002, the highest
proportion reported that cannabis was their main problem drug (Table 5). The second most commonly
reported main problem drug for new cases living in each of the seven health board areas varied; cases living in
the Midland Health Board area and the North Eastern Health Board area reported opiates, while cases in the
remaining health board areas reported ecstasy. This depicts the gradual spread of opiate use outside the Eastern
Regional Health Authority, which will be dealt with in a forthcoming paper. 
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Table 5   Main problem drug reported by new cases* treated in the seven health boards, by
health board of residence, and reported to the NDTRS, 1998 to 2002
Main problem drug MHB MWHB NEHB NWHB SHB SEHB WHB   
Number (%)           
New cases 345 531 630 255 1466 945 176  
Cannabis 198 (57.4) 343 (64.6) 385 (61.1) 165 (64.7) 988 (67.4) 602 (63.7) 88 (50.0)  
Opiates 76 (22.0) 48 (9.0) 116 (18.4) 2 (0.8) 85 (5.8) 73 (7.7) 31 (17.6)  
Ecstasy 48 (13.9) 70 (13.2) 80 (12.7) 70 (27.5) 222 (15.1) 166 (17.6) 40 (22.7)  
Volatile Inhalants 8 (2.3) 16 (3.0) 18 (2.9) 9 (3.5) 46 (3.1) 7 (0.7) 9 (5.1)  
Benzodiazepines 5 (1.4) 7 (1.3) 9 (1.4) 4 (1.6) 44 (3.0) 12 (1.3) 1 (0.6)  
Cocaine 4 (1.2) 16 (3.0) 8 (1.3) 2 (0.8) 35 (2.4) 27 (2.9) 4 (2.3)  
Amphetamines 1 (0.3) 17 (3.2) 7 (1.1) 2 (0.8) 5 (0.3) 40 (4.2) 2 (1.1)  
Other substances 5 (1.4) 14 (2.6) 7 (1.1) 1 (0.4) 41 (2.8) 18 (1.9) 1 (0.6)      
* Numbers exclude cases living in one of the seven health board areas but treated in the Eastern Regional Health Authority. 
Although there was a small proportional decrease in polydrug use, from 84 per cent of cases in 1998 to 79 per
cent in 2002 (Table 6), it remained a common practice and is associated with poorer treatment outcomes. 
Table 6   Use of more than one drug reported by cases* living and treated in the seven health
board† areas, by treatment status and reported to the NDTRS, 1998 to 2002
Used more than one drug 1998    1999   2000 2001 2002   
Number (%)         
All cases 660 (83.7) 755 (77.8) 1268 (81.5) 1523 (77.3) 1777 (78.6)  
Previously treated cases 235 (87.4) 316 (81.4) 470 (83.2) 564 (75.6) 715 (80.7)  
New cases 357 (84.4) 418 (75.2) 768 (80.7) 906 (79.2) 985 (77.4)  
Unknown 68 21 30 53 77         
* Numbers exclude cases living in the Eastern Regional Health Authority but treated in one of the seven health boards and cases living in
one of the seven health board areas but treated in the Eastern Regional Health Authority. 
† Midland Health Board, Mid-Western Health Board, North Eastern Health Board, North Western Health Board, Southern Health Board, South
Eastern Health Board and Western Health Board.
During the reporting period the proportion of new cases who reported polydrug use varied by health board of
residence (Table 7). Ninety–two per cent of cases living in the Southern Health Board reported polydrug use,
while less than two-thirds of the new cases living in the Midland and North Eastern Health Board areas reported
polydrug use. The lower levels of polydrug use among new cases living in the Midland and North Eastern Health
Board areas was surprising, since the highest numbers of opiate users live in these two health board areas. 
Table 7   Use of more than one drug reported by new cases* treated in the seven health boards,
by health board of residence, and reported to the NDTRS, 1998 to 2002
New cases used MHB MWHB NEHB NWHB SHB SEHB WHB   
more than one drug
Number (%)  
New Cases 345 531 630 255 1466 945 176  
Used more than one drug 225 (65.2) 428 (80.6) 388 (61.6) 198 (77.6) 1347 (91.9) 719 (76.1) 129 (73.3)     
* Numbers exclude cases living in one of the seven health board areas but treated in the Eastern Regional Health Authority. 
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Of those cases treated in the seven health board areas between 1998 and 2002 who reported a second
problem drug, cases most frequently reported that alcohol, ecstasy or cannabis was their second problem drug
(Table 8). The number of cases reporting one of these three substances as their second problem drug increased
substantially during the period under review. The numbers reporting amphetamines as their second problem
drug decreased, while the numbers reporting benzodiazepines, cocaine and opiates increased. Previously
treated cases more commonly reported benzodiazepine or opiate use, while new cases more commonly
reported cocaine use.  
Table 8   Second problem drug reported by cases* living and treated in the seven health board†
areas, by treatment status and reported to the NDTRS, 1998 to 2002
Second problem drug 1998  1999  2000  2001 2002   
Number (%)         
All cases 660 755 1268 1523 1776  
Ecstasy 172 (26.1) 233 (30.9) 396 (31.2) 470 (30.9) 467 (26.3)  
Cannabis 153 (23.2) 158 (20.9) 262 (20.7) 336 (22.1) 348 (19.6)  
Alcohol 121 (18.3) 138 (18.3) 289 (22.8) 398 (26.1) 589 (33.2)  
Amphetamines 108 (16.4) 109 (14.4) 108 (8.5) 69 (4.5) 85 (4.8)  
Opiates 21 (3.2) 22 (2.9) 42 (3.3) 47 (3.1) 57 (3.2)  
Cocaine 15 (2.3) 26 (3.4) 54 (4.3) 72 (4.7) 98 (5.5)  
Benzodiazepines 14 (2.1) 22 (2.9) 39 (3.1) 51 (3.3) 59 (3.3)  
Volatile inhalants 2 (0.3) 8 (1.1) 13 (1.0) 18 (1.2) 20 (1.1)  
Other substances 54 (8.2) 39 (5.2) 65 (5.1) 62 (4.1) 53 (3.0)  
Previously treated cases 235 316 470 564 715  
Cannabis 65 (27.7) 70 (22.2) 107 (22.8) 148 (26.2) 158 (22.1)  
Ecstasy 53 (22.6) 76 (24.1) 123 (26.2) 148 (26.2) 157 (22.0)  
Alcohol 37 (15.7) 56 (17.7) 93 (19.8) 129 (22.9) 221 (30.9)  
Amphetamines 31 (13.2) 37 (11.7) 41 (8.7) 23 (4.1) 33 (4.2)  
Opiates 10 (4.3) 17 (5.4) 23 (4.9) 31 (5.5) 39 (5.5)  
Benzodiazepines 10 (4.3) 15 (4.7) 24 (5.1) 34 (6.0) 44 (6.2)  
Cocaine 5 (2.1) 16 (5.1) 27 (5.7) 31 (5.5) 33 (4.6)  
Volatile inhalants 0 (0.0) 3 (0.9) 4 (0.9) 5 (0.9) 9 (1.3)  
Other substances 24 (10.2) 26 (8.2) 28 (6.0) 15 (2.7) 24 (3.4)  
New cases 357 418 768 906 984  
Ecstasy 97 (27.2) 150 (35.9) 261 (34.0) 299 (33.0) 293 (29.8)  
Alcohol 81 (22.7) 77 (18.4) 189 (24.6) 261 (28.8) 350 (35.6)  
Cannabis 76 (21.3) 84 (20.1) 149 (19.4) 182 (20.1) 172 (17.5)  
Amphetamines 62 (17.4) 69 (16.5) 65 (8.5) 43 (4.7) 52 (5.3)  
Cocaine 9 (2.5) 10 (2.4) 27 (3.5) 39 (4.3) 57 (5.8)  
Benzodiazepines 4 (1.1) 6 (1.4) 13 (1.7) 15 (1.7) 14 (1.4)  
Volatile inhalants 2 (0.6) 5 (1.2) 9 (1.2) 13 (1.4) 10 (1.0)  
Opiates 0 (0.0) 4 (1.0) 18 (2.3) 15 (1.7) 18 (1.8)  
Other substances 26 (7.3) 13 (3.1) 37 (4.8) 39 (4.3) 18 (1.8)  
* Numbers exclude cases living in the Eastern Regional Health Authority but treated in one of the seven health boards and cases living in
one of the seven health board areas but treated in the Eastern Regional Health Authority. 
† Midland Health Board, Mid-Western Health Board, North Eastern Health Board, North Western Health Board, Southern Health Board, South
Eastern Health Board and Western Health Board.
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The most common second problem drug reported by new cases living in each of the seven health board areas
varied, with new cases living in the Southern and Western Health Board areas reporting alcohol, while new
cases living in the remaining health boards reported ecstasy (Table 9). New cases living in the Midland and
North Eastern Health Board areas were less likely to report alcohol as a second problem drug than new cases
living in the other five health board areas. 
Table 9   Second problem drug reported by new cases* treated in the seven health boards, by
health board of residence and reported to the NDTRS, 1998 to 2002
Second problem drug MHB MWHB NEHB NWHB SHB SEHB WHB   
Number (%)           
New cases 225 428 388 198 1347 718 129           
Ecstasy 98 (43.6) 153 (35.7) 161 (41.5) 66 (33.3) 384 (28.5)  210 (29.2) 28 (21.7)  
Cannabis 81 (36.0) 70 (16.4) 118 (30.4) 56 (28.3) 181 (13.4) 130 (18.1) 27 (20.9)  
Amphetamines 18 (8.0) 48 (11.2) 38 (9.8) 7 (3.5) 31 (2.3) 143 (19.9) 6 (4.7)  
Alcohol 12 (5.3) 83 (19.4) 9 (2.3) 46 (23.2) 605 (44.9) 163 (22.7) 40 (31.0)  
Cocaine 5 (2.2) 23 (5.4) 10 (2.6) 9 (4.5) 49 (3.6) 33 (4.6) 13 (10.1)  
Opiates 2 (0.9) 3 (0.7) 10 (2.6) 4 (2.0) 21 (1.6) 11 (1.5) 4 (3.1)  
Benzodiazepines 1 (0.4) 9 (2.1) 8 (2.1) 0 (0.0) 18 (1.3) 11 (1.5) 5 (3.9)  
Volatile Inhalants 1 (0.4) 7 (1.6) 13 (3.4) 5 (2.5) 9 (0.7) 1 (0.1) 3 (2.3)  
Other substances 7 (3.1) 32 (7.5) 21 (5.4) 5 (2.5) 49 (3.6) 16 (2.2) 3 (2.3)      
* Numbers exclude cases living in one of the seven health board areas but treated in the Eastern Regional Health Authority. 
Risk behaviours
The number of cases who reported injecting trebled, increasing from 96 in 1998 to 284 in 2002 (Table 10).
This increase was noted among both new and previously treated cases. Between 2000 and 2002, fifty per cent
of injector cases had started injecting before they were 20 years old. In 2002, almost half of all injector cases
had shared injecting equipment. As expected, a higher proportion of previously treated injector cases shared
injecting equipment than their new injector counterparts. Injectors have a higher risk of acquiring blood-borne
viral infections and experiencing overdose than non-injectors. There are no reliable data on the incidence or
prevalence of blood-borne viral illnesses among injecting drug users living outside the Dublin area. There was a
steady increase in the number of drug-related deaths outside Dublin, from four in 1995 to 33 in 2001
(unpublished data from the Central Statistics Office). 
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Table 10   Risk behaviours reported by cases* living and treated in the seven health board†
areas, by treatment status and reported to the NDTRS, 1998 to 2002
Injecting and sharing status 1998 1999 2000 2001 2002
All cases injector 
status known 685 919 1499 1906 2180
Median age (range)‡
started drug use, in years 15 (12-23) 15 (12-22) 15 (11-22) 15 (12-22) 15 (11-23)
Median age (range)‡
started injecting, in years 20 (15-28) 19 (15-28) 20 (15-30) 20 (15-34) 20 (15-28)
Number (%) ever injected 96 (14.0) 124 (13.5) 186 (12.4) 255 (13.4) 284 (13.0)
Of whom:§
‘ever shared’ 42 (43.8) 49 (39.5) 93 (50.0) 136 (53.3) 137 (48.2)
‘currently injecting’  33 (34.4) 32 (25.8) 66 (35.5) 94 (36.9) 99 (34.9)
‘currently sharing’  8 (8.3) 6 (4.8) 18 (9.7) 30 (11.8) 18 (6.3)
Previously treated cases 
injector status known 245 365 545 723 863
Median age (range)‡
started drug use, in years 15 (11-24) 15 (12-23) 15 (11-23) 15 (12-22) 15 (11-23)
Median age (range)‡
started injecting, in years 20 (14-36) 20 (15-28) 20 (16-30) 20 (15-34) 20 (15-27)
Number (%) ever injected 49 (20.0) 89 (24.4) 117 (21.5) 178 (24.6) 193 (22.4)
Of whom:§
‘ever shared’ 21 (42.9) 40 (44.9) 63 (53.8) 107 (60.1) 102 (52.8)
‘currently injecting’  15 (30.6) 23 (25.8) 37 (31.6) 64 (36.0) 60 (31.1)
‘currently sharing’  4 (8.2) 4 (4.5) 12 (10.3) 22 (12.4) 13 (6.7)
New cases injector 
status known 398 539 926 1123 1235
Median age (range)‡
started drug use, in years 15 (12-21) 15 (11-22) 15 (11-21) 15 (12-22) 15 (11-22)
Median age (range)‡
started injecting, in years ** 18 (15-29) 21 (15-30) 21 (15-35) 20 (15-30)
Number (%) ever injected 24 (6.0) 29 (5.4) 59 (6.4) 69 (6.1) 76 (6.2)
Of whom:§
‘ever shared’ 9 (37.5) 8 (27.6) 26 (44.1) 26 (37.7) 32 (42.1)
‘currently injecting’  4 (16.7) 7 (24.1) 24 (40.7) 25 (36.2) 34 (44.7)
‘currently sharing’  1 (4.2) 1 (3.4) 6 (10.2) 8 (11.6) 5 (6.6)
* Numbers include cases living in the Eastern Regional Health Authority but treated in another health board area, and exclude cases living in
one of the seven health board areas but treated in the Eastern Regional Health Authority and recorded in the NDTRS.
† Midland Health Board, Mid-Western Health Board, North Eastern Health Board, North Western Health Board, Southern Health Board, South
Eastern Health Board and Western Health Board. 
‡ Age range presented is the 5th to 95th percentile (90% of all cases are within this age range).
§ From the data presented in this table, it is not possible to ascertain the exact percentage of injectors with each risk factor of interest
because not all declared injectors were asked the subsequent injecting questions. 
** Not possible to calculate because of the small number of cases.
The highest number of new injector cases lived in the South Eastern Health Board area, followed closely by the
North Eastern Health Board area (Table 11). Of new cases reporting problem drug use, the highest proportion
of injectors lived in the Midland and Western Health Board areas. 
Table 11   Risk behaviours reported by new cases* treated in the seven health board areas, by
health board of residence and reported to the NDTRS, 1998 to 2002
Injecting and sharing status MHB MWHB NEHB NWHB SHB SEHB WHB
New cases
– injector status known 336 494 614 245 1441 917 174
Median age (range)†
started drug use, in years 15 (12-20) 15 (11-21) 15 (11-20) 15 (11-21) 15 (11-24) 15 (12-24) 15 (12-22)
Median age (range)†
started  injecting, in years 20 (16-29) 25 (13-33) 21 (15-27) § 20 (16-35) 22 (16-37) §
Number (%) ever injected 35 (10.4) 27 (5.5) 57 (9.3) 6 (2.4) 54 (3.7) 59 (6.4) 19 (10.9)
Of whom:‡
‘ever shared’ 15 (42.9) 11 (40.7) 27 (47.4) 2 (33.3) 15 (27.8) 26 (44.1) 5 (26.3)
‘currently injecting’  14 (40.0) 14 (51.9) 20 (35.1) 1 (16.7) 19 (35.2) 19 (32.2) 7 (36.8)
‘currently sharing’  6 (17.1) 3 (11.1) 2 (3.5) 0 (0.0) 4 (7.4) 6 (10.2) 0 (0.0)
* Numbers exclude cases living in one of the seven health board areas but treated in the Eastern Regional Health Authority
† Age range presented is the 5th to 95th percentile (90% of all cases are within this age range).
‡  From the data presented in this table, it is not possible to ascertain the exact percentage of injectors with each risk factor of interest
because not all declared injectors were asked the subsequent injecting questions. 
§ Not possible to calculate because of the small number of cases.
Socio-demographic characteristics
The median age of previously treated cases attending drug treatment services in the seven health boards
increased by over two years, while the median age of new cases increased by six months between 1998 and
2002 (Table 12). The proportion of cases less than 18 years of age increased by just over three per cent over
the reporting period. As expected, the proportion of cases less than 18 years of age was much higher among
new cases than among those previously treated. Overall, 79 per cent of cases who attended drug treatment
services were male. From 2000 to 2002, the proportion of previously treated cases who lived with their parents
or family decreased, while the proportion of new cases who lived with parents or family remained constant.
The proportion of previously treated cases reporting that they were homeless decreased steadily between 1999
and 2002. Overall, 19 per cent of cases treated in the period under review had left school early.  It is clear that
early school leavers are over-represented among those seeking treatment for problem drug use and this is an
important factor for social and occupational rehabilitation interventions and securing employment.  The
proportions were marginally higher among previously treated cases when compared to new cases. From 1998
to 2002, the proportion of new cases reporting that they were employed followed national trends, with rates
increasing up to 2001 and decreasing by three per cent in 2002. Of note, employment rates were higher
among new cases compared to their previously treated counterparts, indicating that those with chronic drug
problems may be less likely to find or retain employment. 
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Table 12   Socio-demographic characteristics of cases* living and treated in the seven health
board† areas by treatment status and reported to the NDTRS, 1998 to 2002   
Characteristics‡ 1998 1999 2000 2001 2002
All cases‡ 789 970 1556 1969 2261
Median age (range)§ in years 21.6 (16.5-39.2) 22.0 (16.2-38.5) 22.1 (16.0-39.9) 22.6 (15.8-41.0) 23.0 (15.6-41.5)
Number (%) under 18 years of age 122 (15.6) 160 (16.6) 276 (17.8) 340 (17.3) 420 (18.7)
Number (%) of males 606 (79.2) 753 (78.3) 1229 (79.4) 1522 (77.9) 1745 (80.2)
Number (%) living with parents/family 438 (55.5) 609 (62.8) 959 (61.6) 1151 (58.5) 1339 (59.2)
Number (%) homeless ** 56 (5.8) 77 (4.9) 69 (3.7) 63 (3.0)
Number (%) of early school leavers†† 78 (15.1) 126 (18.9) 237 (19.8) 305 (20.7) 287 (17.4)
Number (%) still in school 57 (9.9) 76 (10.2) 142 (10.6) 179 (10.8) 288 (14.9)
Number (%) aged 16 to 64 
years employed 233 (31.5) 268 (29.4) 501 (35.0) 637 (35.2) 650 (31.8)
Previously treated cases‡ 269 388 565 746 886
Median age (range)§ in years 23.3 (16.8-43.0) 24.6 (17.2-43.5) 23.6 (16.8-41.4) 25.0 (17.1-42.2) 25.4 (16.8-46.4)
Number (%) under 18 years of age 30 (11.2) 33 (8.5) 61 (10.8) 66 (8.9) 83 (9.4)
Number (%) of males 201 (77.3) 291 (75.8) 433 (76.6) 564 (76.1) 671 (78.3)
Number (%) living with parents/family 150 (55.8) 205 (52.8) 306 (54.2) 353 (47.3) 434 (49.0)
Number (%) homeless ** 28 (7.2) 33 (5.8) 33 (4.7) 28 (3.4)
Number (%) of early school leavers†† 33 (17.6) 53 (20.0) 92 (20.4) 137 (23.6) 137 (20.1)
Number (%) still in school 14 (6.9) 9 (3.3) 26 (5.4) 27 (4.4) 51 (6.9)
Number (%) aged 16 to 64 
years employed 64 (24.4) 81 (21.7) 157 (29.6) 210 (29.7) 241 (29.0)
New cases‡ 423 556 952 1144 1273
Median age (range)§ in years 20.8 (16.4-37.6) 20.9 (15.8-34.1) 21.2 (15.7-38.2) 21.1 (15.3-38.2) 21.3 (15.3-37.4)
Number (%) under 18 years of age 79 (18.8) 122 (22.1) 212 (22.3) 267 (23.4) 331 (26.2)
Number (%) of males 336 (80.6) 442 (79.8) 764 (80.8) 891 (78.6) 1000 (80.9)
Number (%) living with parents/family 280 (66.2) 392 (70.5) 628 (66.0) 766 (67.0) 851 (66.8)
Number (%) homeless ** 23 (4.1) 40 (4.2) 27 (2.4) 23 (1.9)
Number (%) of early school leavers†† 44 (13.7) 68 (17.4) 138 (19.2) 155 (18.4) 138 (15.2)
Number (%) still in school 35 (9.8) 66 (14.5) 113 (13.6) 150 (15.1) 234 (20.5)
Number (%) aged 16 to 64 
years employed 135 (33.9) 183 (35.6) 337 (38.7) 402 (39.0) 384 (34.2)
* Numbers include cases living in the Eastern Regional Health Authority but treated in another health board area, and exclude cases living in
one of the seven health board areas but treated in the Eastern Regional Health Authority and recorded in the NDTRS.
† Midland Health Board, Mid-Western Health Board, North Eastern Health Board, North Western Health Board, Southern Health Board, South
Eastern Health Board and Western Health Board. 
‡ It is not possible to ascertain the percentage with each characteristic of interest from the total number because not all forms had
complete data. 
§ Age range presented is the 5th to 95th percentile (90% of all cases are within this age range).
** Data not available.
†† Left school before the age of 15 years.
The socio-demographic characteristics of new cases attending treatment, by health board of residence (and
reported to the NDTRS), were examined (Table 13). Over one-third of new cases treated for problem drug use
and living in the Western Health Board area were less than 18 years old between 1998 and 2002. This may
reflect the age group that used illicit drugs, the types of services provided or the type of services that submitted
data to the NDTRS in this health board area. Over one-quarter of new cases living in the North Eastern Health
Board, North Western Health Board and Southern Health Board areas were less than 18 years old. During the
reporting period, 24 per cent of new cases living in the Southern Health Board were female, while only 15 per
cent of cases living in the South Eastern Health Board were female. This may indicate gender differences in
either illicit drug use or treatment seeking for problem drug use in different health board areas. 
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The proportion of new cases living with parents or family also varied across health board areas during the period
under review. With the exception of the North Eastern Health Board, the health boards with higher proportions
of drug users living with their parents and family were not the health boards with higher proportions of young
drug users. Overall, the proportion of new cases living in the North Western Health Board who left school early
was very small and the explanation for this is not clear. Between 1998 and 2002, a high proportion of new cases
living in the North Eastern Health Board were employed, while a low proportion living in the Mid-Western Health
Board and Western Health Board were employed. 
Table 13   Socio-demographic characteristics of new cases* treated in the seven health board
areas, by health board of residence reported to the NDTRS, 1998 to 2002 
New cases characteristics† MHB MWHB NEHB NWHB SHB SEHB WHB
New cases 345 531 630 255 1466 945 176
Median age (range)‡ 21 21.5 20.6 20.6 21.0 21.6 20.5
in years (16.3-33.1) (15.9-36.4) (15.1-35.2) (15.6-33.7) (15.2-41.0) (16.1-36.4) (14.7-39.1)
Number (%) under 63 101 169 67 383 166 62
18 years of age (18.4) (19.1) (27.1) (26.5) (26.1) (17.6) (35.4)
Number (%) of males 284 422 495 192 1104 803 133 
(83.3) (80.1) (82.4) (77.4) (75.9) (85.2) (76.4)
Number (%) living 238 372 476 170 948 607 106 
with parents/family (69.0) (70.1) (75.6) (66.7) (64.7) (64.2) (60.2)
Number (%) of 55 71 60 14 207 121 15 
early school leavers§ (20.4) (18.5) (16.0) (7.9) (19.4) (15.1) (13.9)
Number (%) 37 68 90 44 216 97 46
still in school (12.1) (15.0) (19.4) (19.9) (16.8) (10.8) (29.9)
Number (%) aged 16 to 126 135 253 73 469 343 42
64 years employed (39.4) (27.8) (46.2) (32.0) (35.9) (38.3) (27.6)
* Numbers exclude those living in one of the seven health board areas but treated in the Eastern Regional Health Authority. 
† It is not possible to ascertain the percentage with each characteristic of interest from the total number because not all forms had complete
data. 
‡ Age range presented is the 5th to 95th percentile (90% of all cases are within this age range).
§  Left school before the age of 15 years.
Relationship between main problem drug and selected characteristics 
In order to highlight important relationships, the main problem drug was examined by selected socio-
demographic characteristics. Figures 3a and 3b present the age at which new cases commenced use of their
main problem drug in the seven health board areas for the period 1998 to 2002. It is clear that young teenagers
initiated drug use with cannabis and, to a lesser extent, ecstasy and volatile inhalants. The use of opiates and
amphetamines commenced in mid to late teens. The number reporting benzodiazepines and cocaine as their
main problem drug was small, but these are more common as second drugs. Benzodiazepines and cocaine are
also more common among older and previously treated problem drug users. 
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Figures 4a and 4b present the age at which new cases sought treatment in the seven health board areas, by
the main problem drug, for the period 1998 to 2002. Although the numbers using volatile inhalants are small,
it is the main problem drug for a very young client group. It is clear that cannabis and ecstasy are the drugs
that young people seek treatment for in the late teens, while the majority of opiate users seek treatment in their
early twenties. Taken together, Figures 3a and 3b and Figures 4a and 4b present the delay between initiation of
the main problem drug (such as cannabis and opiates) and seeking treatment for it. 
Figure 3a   Age commenced use of main 
problem drug for new cases living and treated
in the seven health board areas and reported 
to the NDTRS, 1998 to 2002
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Figure 3b   Age commenced use of main problem
drug (excluding cannabis) for new cases living
and treated in the seven health board areas and
reported to the NDTRS, 1998 to 2002
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Figure 4a   Age attended first treatment by
main problem drug for new cases living and
treated in the seven health board areas and
reported to the NDTRS, 1998 to 2002
0
50
100
150
200
250
300
350
14
 ye
ar
s
or
 le
ss 15
-1
9
20
-2
4
25
-2
9
30
-3
4
35
-3
9
40
-4
4
45
-4
9
50
 ye
ar
s
or
 m
or
e
Ecstasy
Volatile inhalants
Opiates
Amphetaminess & cocaine
Benzodiazepines
N
um
be
r 
of
 c
as
es
Age in years
Figure 4b   Age attended first treatment by main
problem drug (excluding cannabis) for new cases
living and treated in the seven health board areas
and reported to the NDTRS, 1998 to 2002
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Figure 5 presents the gender of new cases who sought treatment in the seven health board areas, by the main
problem drug, for the period 1998 to 2002. The proportion of males treated for cocaine and cannabis use was
very high compared to that of their female counterparts. Although the proportion of males treated for opiate
and benzodiazepine use was higher than the proportion of females, the gender difference pertaining to the use
of these drugs was not as striking as that pertaining to cocaine and cannabis. 
Figure 5   Main problem drug, by gender, for new cases living and treated in the seven health
board areas and reported to the NDTRS, 1998 to 2002
Figure 6 presents the employment status of new cases who sought treatment, by the new main problem drug,
for the period 1998 to 2002. The highest rates of employment were among those who used drugs commonly
associated with social events, and the lowest rates of employment were among those who used opiates and
benzodiazepines. This has important implications for the social and occupational reintegration of opiate and
benzodiazepine users. 
0
10
20
30
40
50
60
70
80
90
100
Pe
rc
en
ta
ge
Male
Female
Co
ca
ine
Ca
nn
ab
is
Am
ph
et
am
ine
s
Ec
sta
sy
Op
iat
es
Vo
lat
ile
 in
ha
lan
ts
Be
nz
od
iaz
ep
ine
s
89.6
83.9
79.5 77.7
71.2
60.0 59.3
10.4
16.1
20.5 22.3
28.8
40.0 40.7
0
5
10
15
20
25
30
35
40
45
50
Pe
rc
en
ta
ge
 e
m
p
lo
ye
d
Ec
sta
sy
Co
ca
ine
Am
ph
et
am
ine
s
Ca
nn
ab
is
Op
iat
es
Be
nz
od
iaz
ep
ine
s
Vo
lat
ile
 in
ha
lan
ts
43.9 43.8 43.8
36.1
31.0
25.6
9.1
Figure 6   Main problem drug, by regular employment, for new cases aged between 16 and 64 years
living and treated in the seven health board areas and reported to the NDTRS, 1998 to 2002
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Figure 7 presents the route of administration for their main problem drug reported by new cases who sought
treatment between 1998 and 2002. Injecting drug use was associated with opiates and to a lesser extent with
amphetamines. Of the new cases reporting cocaine or benzodiazepines as their main problem drug, none
reported injecting either drug. The route of administration was examined for new cases reporting cocaine and
benzodiazepines as a second drug; six per cent (9/152) of cases reported injecting cocaine as a second drug
and only two per cent (1/54) of cases reported injecting benzodiazepines as a second drug.   
Figure 7   Route of administration for selected main problem drugs for new cases living and
treated in the seven health board areas and reported to the NDTRS, 1998 to 2002
Conclusions
Both the incidence and prevalence of treated problem drug use almost trebled between 1998 and 2002.  The
incidence of treated problem drug use for the reporting period was highest in the Southern Health Board area,
followed closely by the South Eastern Health Board area, while the Western Health Board area had the lowest
incidence. 
Overall, new and previously treated cases in the seven health board areas between 1998 and 2002 most
frequently reported that cannabis was their main problem drug. The numbers reporting problem opiate use
also increased steadily.  The second most frequently reported main problem drug was ecstasy for new cases and
opiates for previously treated cases. Though small, the number of new cases reporting cocaine increased from 6
in 1998 to 42 in 2002, indicating the early stages of an epidemic. 
These findings indicate that treatment services need to cater for a wide spectrum of illicit drugs rather than
focus on one or two drugs and must be capable of adjusting treatment approaches in accordance with changing
patterns of problem drug use. Polydrug use remained a common practice and must also be addressed in
treatment plans. The numbers and proportion of cases under 18 years old increased; these young people require
different approaches to treatment and it is important that this is included in service planning.  The number of
cases who reported injecting almost trebled.  Injectors have a higher risk of acquiring blood-borne viral infections
and experiencing overdose than non-injectors. Reliable data on the incidence or prevalence of blood-borne viral
illnesses and drug-related deaths for those living outside the Dublin area are required. 
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Conclusions (continued)
The main problem drug reported by new cases was examined by selected socio-demographic and drug-using
characteristics and some important relationships were identified. Young teenagers initiated drug use with cannabis
and volatile inhalants. The use of opiates, ecstasy and amphetamines was commenced in mid to late teens. There
were differences in type of drug used by males and females, with very high proportions of males treated for
cocaine and cannabis use compared to their female counterparts. The highest rates of employment were among
those using drugs commonly associated with social events and the lowest rates of employment were among those
who used opiates and benzodiazepines; this observation, along with the high rates of early school leaving, has
important implications for the social and occupational reintegration of opiate and benzodiazepine users.  
These treatment data are important to guide future drug policy and planning.  They will provide useful information
for the upcoming review of the national drugs strategy and provide baseline data for the regional drugs task forces.
The increasing importance of alcohol as a second problem drug and the overlap between problem alcohol and
drug use point to the need for an integrated approach to the management of substance misuse.  
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